SLT for glaucoma SEO Brief & AI Prompts

Selective laser trabeculoplasty (SLT) is a laser procedure used to treat open-angle glaucoma by applying low-energy, frequency-doubled 532 nm pulses to the trabecular meshwork to lower intraocular pressure, typically producing an intraocular pressure reduction of about 20–30%. The procedure is performed in an outpatient clinic, usually taking only a few minutes per eye under topical anesthesia, and can be repeated because it causes minimal structural damage to the trabecular meshwork. SLT is commonly offered as initial therapy or as an adjunct when topical medical therapy fails or causes intolerable side effects. Common short-term side effects include mild inflammation and transient intraocular pressure spikes that are usually managed with topical medications.

SLT lowers intraocular pressure by stimulating a localized biologic response in pigmented cells of the trabecular meshwork rather than creating direct thermal burns; this principle of selective photothermolysis contrasts with the coagulative damage produced by argon laser trabeculoplasty (ALT). The procedure uses a frequency‑doubled 532 nm Q‑switched laser and is titrated by spot size and energy to produce microscopic cellular effects that increase aqueous outflow. Clinicians track intraocular pressure reduction with Goldmann applanation tonometry and monitor inflammatory response with slit‑lamp examination. Major societies such as the American Academy of Ophthalmology include SLT for glaucoma in treatment algorithms as initial or adjunctive therapy for primary open‑angle glaucoma and ocular hypertension.

A common misperception is that SLT is simply a drop replacement; in practice effectiveness and durability vary with baseline pressure, angle anatomy, and prior surgeries. For example, patients with primary open‑angle glaucoma and a pre‑treatment IOP in the mid‑20s are more likely to achieve a 20–30% intraocular pressure reduction than those with low‑teens baseline pressures, so medication reduction is not guaranteed. Compared with ALT, SLT causes less coagulative damage to trabecular meshwork and is more amenable to repeat treatments, a key point in SLT vs ALT decision‑making. Laser trabeculoplasty risks benefits analysis should therefore weigh probable medication reduction, the chance of short‑term IOP spikes and inflammation, and the need for future surgical options. Long‑term data show variable durability, often lasting about one to three years before additional treatment is considered.

Decision‑making begins by confirming diagnosis of primary open‑angle glaucoma or ocular hypertension, measuring baseline intraocular pressure with Goldmann applanation tonometry, documenting optic nerve and visual field status, and performing gonioscopy to confirm an open angle. If target IOP is unmet or topical therapy causes intolerance, SLT for glaucoma is a reasonable option to lower pressure by about 20–30% and potentially reduce medications; the balance of laser trabeculoplasty risks benefits should be reviewed, including transient IOP spikes and inflammation. Post‑procedure follow‑up typically includes same‑day pressure check and visits at one to three months. This page provides a structured, step‑by‑step framework.